No match scores
Peptide finder
Plate 11
Goal map
Find by outcome
36
Goal pages
1
Record
The short answer
Pick what you want to change. See every compound measured for it in people, most people first. Each one shows what the study found, and the failures are counted. 70 of 453 compounds here have no study in people of any kind.
- Compounds
- 453
- No study in people
- 70
How this ranks
No match scores
Other tools print a match percentage. Nobody measured those numbers. This page shows how many people each goal was measured in, and names the goals nobody has measured in a person.
A thin record in people is usually about who pays for trials. It is not a verdict on the compound.
What users report sits next to the trial count. It is never added into it.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.
Somebody handed you a stack. What is actually known about it?
Add what you are looking at. You get every goal those compounds have been measured for in people. Then you get the longer list of goals they have not.
Bone strength
Does it protect bone?
Bone density is a scan result. Fracture is an event. Trials that measured fractures are worth far more than trials that measured density, and this separates them.
9,203 people · 12 studies in people · 9 compounds
- 01Zoledronic acidSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 4 completed trials, 7,176 people given it.5,065 people3 studies
The bone drip prevented broken bones in older women with thinning bones. Two thousand New Zealand women aged 65 and over got four infusions of either the drug or plain salt water over six years, spaced eighteen months apart. Fragility fractures happened in 122 women on the drug and 190 on salt water. Roughly fifteen...
New England Journal of Medicine, 2018 · 2,000 people
Fewer heart attacks, cancers and deaths turned up on the bone drip, but this was a side look, not the question the trial asked. It re-counted the illnesses and harms recorded in the same two thousand women. Heart attacks fell from 39 women to 24. Cancers fell by about a third. Deaths leaned lower without being clearly...
Journal of Bone and Mineral Research, 2020 · 2,000 people
A once a year bone drip after a broken hip cut later fractures, and fewer people died. Around two thousand people, average age in their mid seventies, got the drip or a dummy one within three months of hip surgery, then were followed about two years. New fractures hit about 9 in every hundred on the drug and about 14...
New England Journal of Medicine, 2007 · 1,065 people
- 02PioglitazoneSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 9,114 people given it.5 reported3,876 people1 study
In people with insulin resistance but no diabetes who had just had a stroke or a mini-stroke, pioglitazone lowered the chance of another stroke or a heart attack over about five years. It also halved new diabetes. It cost more weight gain, swelling and broken bones. Death rates were about the same.
The New England Journal of Medicine, 2016 · 3,876 people
- 03DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported243 people2 studies1 found nothing
found nothingThe biggest study of DHEA against a dummy pill as an anti-ageing supplement found nothing that mattered. 144 older men and women with low levels took it for two years. The hormone went up and little else changed. Body shape, strength, fitness, blood sugar control and quality of life did not get better. Bone density...
The New England Journal of Medicine, 2006 · 144 people
Frail older women given DHEA along with gentle exercise got a little stronger in the legs. Bone density did not change over six months. Small and short. Everyone exercised, so this compares DHEA plus exercise against exercise alone.
Journal of the American Geriatrics Society, 2010 · 99 people
- 04SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported19 people1 study1 found nothing
found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...
Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people
- 05ResveratrolSupplementModerate. At least one finished study in people, and at least 100 people who took it. 14 completed trials, 403 people given it.7 reportednumber of people not given1 study
The same trial found a real gain in bone. After a year on 75 mg twice daily, bone density in the lower spine rose against the dummy, the hip score improved a little, and a marker of bone being broken down fell. Estimated ten year fracture risk came down. Women with the worst bone markers gained most, as did those also...
Journal of Bone and Mineral Research, 2020 · number of people not given
- 06Thymalin with epitalonBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,106 people given it.7 reportednumber of people not given1 study
This is the study the thymalin story rests on, and it is not built to carry that weight. 266 older people were followed for six to eight years, and given thymalin and epithalamin in the first two or three. Infections and deaths were reported at about half the rate of a comparison group, and several age-related...
Neuro Endocrinology Letters, 2003 · number of people not given
- 07MK-677Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 65 people given it.11 reportednumber of people not given1 study
The trial was stopped early over a heart safety signal, and most of what it measured did not improve. 123 older people recovering from a broken hip took MK-677 or a dummy pill. Walking speed improved and IGF-1 rose. Most other measures of function did not move. The study was halted before it finished because of...
Archives of Gerontology and Geriatrics, 2011 · number of people not given
- 08OxandroloneHormonePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.5 reportednumber of people not given1 study
Oxandrolone left badly burned children with stronger bones five years later. 119 children with burns over 30 percent of their body got the drug twice a day for up to two years, or a dummy pill. Treated children had stronger bones across the whole body and lower spine, and grew taller faster early on. Fewer had bones...
Shock, 2016 · number of people not given
- 09Vitamin K2SupplementPreliminary. Studied in people, but no published study has had people take it. 2 human studies where nobody was given it.1 reportednumber of people not given1 study
Healthy women past menopause who took a low dose of K2 for three years lost less bone. That is bone density, not broken bones, and it was not a test of living longer.
Osteoporosis International, 2013 · number of people not given
- 10Nandrolone decanoateHormoneLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, none stating how many people.6 reportednumber of people not given0 studies
How this is counted
Studies in people only. Animal and lab work never goes into this ranking, because your question was about a person.
A compound is listed for a goal only when a study on its own page names that goal and reports a result for it. Just naming it is not enough. Say a paper measures testosterone but reports a result about something else. That does not count as testosterone evidence. This tool made that mistake on its first run, and it no longer does.
People counts come from the study lines themselves, and when in doubt they count low. If a line gives no number, the study still counts as a study but adds nobody to the people count. Counts are never added up across compounds, because the same person can be in more than one trial.
The order is by how many people were measured. That is a fact about the evidence, not a judgement about the compound. It is the only order this site will defend. A compound at the top of a list is the most studied. That is not the same as the best.
Nothing here is advice. Nothing here tells you to take anything.